NEW YORK (GenomeWeb News) – Chromatide and Novasep have agreed to extend a research partnership focused on developing peptide and oligonucleotide synthesis technology, Novasep said Friday.
Novasep said the companies plan to combine its synthesis and purification services, which pharmaceutical companies use to produce pure peptides and oligonucleotides, with Chromatide’s experience in peptide and oligonucleotide synthesis, including production of novel resins and instruments.
“Peptide manufacturers lack a cost efficient, automated solid phase synthesis technology,” explained Novasep Process Pharma Business Unit President Jean Blehaut, adding that the combined systems “will allow us to provide a unique, global process solution for peptides” and for oligonucleotide makers.
Novasep plans to launch the synthesis systems the companies have developed later this year, Chromatide CSO Don Wellings said in a statement.